McKesson's fiscal second quarter cleared the bar most of the Street set but not the one investors set. Adjusted EPS of $11.68 rose 18.5% year over year and comfortably topped the $10.69 consensus. It still came in 0.4% below the $11.73 Earnings Whisper number, a technical miss against an elevated expectation. Revenue of $110.96 billion grew 7.6% and beat consensus by 0.8%. The narrow whisper shortfall is the least important part of the report. That is the central tension: a stock priced for a big beat delivered a slightly smaller one, while the underlying business and the full-year outlook improved meaningfully.

The quality of the quarter is better than the headline surprise implies. Management said adjusted EPS grew 24% excluding prior-year items, so the 18.5% reported growth understates the operating trend. Free cash flow swung to $2.9 billion from negative $372 million in the first quarter. That keeps the $4.5 to $4.9 billion full-year target intact and supports roughly $5 billion of buybacks, of which $3.4 billion is already done. The full-year adjusted EPS guide rose to $45.60 to $46.40. That compares with $44.20 to $45.00 after the first quarter and $43.80 to $44.60 at the initial outlook. The raised range implies 19% to 21% growth excluding items, well above the company's 13% to 16% long-term target.

The call showed growth accelerating, not just holding. North American Pharmaceutical operating profit grew about 22%, up from 19% in the first quarter and 11% in the fourth quarter of fiscal 2026. The segment's full-year profit growth guide jumped to 14% to 18% from the high end of 5.5% to 9.5%. GLP-1 distribution revenue climbed to $16 billion, up 26% year over year and from $15 billion and $14 billion in the two prior quarters. Oncology & Multispecialty was equally strong:

• Revenue rose 24%.
• Operating profit rose 23% excluding gains.
• Same-store patient visits were at recent highs.
• The revenue guide was lifted to 20% to 24%.

RxTS operating profit growth accelerated to 18% from 13%. Consolidated operating profit growth guidance now stands at 12% to 16%, versus 9% to 13% a quarter ago.

The soft spots are real but contained. Medical-Surgical operating profit fell 10% on ambulatory product mix, and the full-year guide was cut to a 4% decline to flat from flat to up 4%. Interest and corporate expense are now expected at the high end of their ranges. Management is also accelerating second-half investment in pharma and oncology, which could temper margin leverage. Bears have legitimate ammunition elsewhere too:

• Pharma profit growth is running far above its 5% to 8% long-term target, which raises sustainability questions.
• GLP-1 Bridge Program prior authorization volumes are normalizing after an initial surge.
• A possible January 2027 340B rebate model adds policy uncertainty, though management sees no material impact.

Strategically, McKesson took on more ambition. It closed the roughly $2.25 billion Precision Medicine Group acquisition, its first entry into contract research. Management expects the deal to add $0.10 to $0.20 to fiscal 2027 EPS and $1.60 to $1.80 of accretion by year three, though integration risk comes with it. The company also agreed to take a 49% stake in Option Care Health alongside CD&R for about $1.4 billion. That deal is expected to close in the first half of calendar 2027 and is not in guidance. Separately, McKesson extended its CVS Health distribution contract through June 2032, removing a key customer overhang.

The market setup is more complicated than the fundamentals alone suggest. Investor sentiment turned more negative heading into the report, falling from roughly neutral at -0.01 to -0.15. That is a noticeable cooling even as the stock kept climbing. Shares were up 9.6% since the open after the prior report and sat 15.7% above the 200-day moving average. They traded about 3% below the $1,030.27 52-week high set on October 20, near the top of an inter-earnings range that bottomed at $837.88 in August. The Earnings Whispers trend signals were uniformly positive. That combination of a stretched price, an aggressive whisper number and fading enthusiasm helps explain why a 9% consensus beat could still register as a miss.

The bottom line is that McKesson delivered its second straight beat-and-raise, with accelerating profit growth in its two largest engines and guidance now well above long-term targets. The whisper shortfall reflects how high expectations had climbed, not any break in the story. The open questions are durability: how sustainable the GLP-1-driven pharma growth is, how Med-Surg stabilizes, and how cleanly management executes the move into CRO and home infusion.